(June 14, 2024) – The Food and Drug Administration
advised manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines for use in the United States, beginning in fall 2024, should be monovalent JN.1 vaccines to more closely match currently circulating SARS-CoV-2 viruses. The FDA's recommendation to manufacturers comes after the FDA Vaccines and Related Biological Products Advisory Committee met on June 5 to discuss and make recommendations on the selection of the 2024-2025 Formula for COVID-19 vaccines for use in the United States beginning this fall. The committee unanimously voted to recommend a monovalent JN.1-lineage vaccine composition. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices is scheduled to discuss the issue on
June 27.
--
Karen Braman